The Impact of Digitalization in Pharmaceutical Regulatory Affairs

by Andrea Bartolomei, Regulatory Operational Excellence Manager @PQE Group

In the fast-paced world of pharmaceuticals, the digital revolution (hyperlink 1) has significantly impacted various aspects of the pharmaceutical industry, including regulatory affairs. As the pharma sector becomes increasingly complex(Hyperlink 2), the adoption of digital technologies has an important impact on the way regulatory affairs professionals operate (hyperlink 3).  

Digital landscape (#eCTD, #digital, #gateway, #digital process; #real-time information) 

Electronic Common Technical Documents (eCTD) and electronic submission gateways have become the norm, leading to faster and more efficient regulatory submissions, but a new step has entered the digitalization process that has revolutionized regulatory processes in the pharmaceutical industry. The main aspects of digitalization processes in which manner the documents are managed have a direct impact on data collection and submission processes, reducing the likelihood of errors and expediting approval timelines.  

Indeed, regulatory affairs professionals can access real-time information, allowing them to make data-driven decisions. This enables them to identify potential risks early, respond to changing regulations swiftly, and proactively address compliance issues. 

Digitalization in Pharmaceutical Regulatory Affairs_Site Banner
EMA actions (# SPOR, #IDMP, #CTIS, #ePI, #DADI) 

European Medicines Agency (EMA) has been actively exploring and proposing various digitalization initiatives within regulatory affairs. EMA's efforts aim to leverage the benefits of digital transformation to streamline processes, enhance patient safety, and improve collaboration between stakeholders.  EMA’s primary key digitalization initiatives are reported below. 

  • SPOR (Substance, Product, Organization and Referential): SPOR is a comprehensive program aimed at improving the identification and management of medicinal products throughout their lifecycles. It includes the development of a central repository for standardized product information, which would facilitate data sharing and reduce duplication of efforts. 
  • ISO IDMP (Identification of Medicinal Products): The ISO IDMP standards are being implemented to establish a common global language for identifying and describing medicinal products. This initiative aims to improve the accuracy and consistency of regulatory data. 
  • Clinical Trials Information System (CTIS): The CTIS is a centralized system designed to streamline the management of clinical trial information within the European Union. It aims to simplify the submission and assessment of clinical trial data. 
  • ePI (Electronic Product Information): EMA has been working on digitizing product information leaflets (PILs) to provide patients and healthcare professionals with easy access to up-to-date information about medicines. 
  • Digital Application Dataset Integration (DADI) project: DADI will replace PDF electronic application forms (eAF) used for regulatory submissions with online forms, making the future form-filling and submission-handling process more efficient. 
How to be ready? (#publishing, #eDMS, #RIMS, #CTMS) 

Digitalization in pharmaceutical regulatory affairs therefore has an impact on the use of various tools and software solutions to streamline processes, improve efficiency, and enhance compliance. Below are some key tools commonly used in pharmaceutical regulatory affairs: 

  • Electronic Submission Software: These tools are essential for creating and submitting electronic regulatory dossiers in formats like eCTD. They help ensure that submissions are compliant with regulatory standards.  
  • Electronic Document Management Systems (EDMS): EDMS software helps manage and organize electronic regulatory documents, ensuring easy access, version control, and compliance with document retention requirements. EDMS is commonly used in various industries for general document management purposes. 
  • Regulatory Information Management (RIM) Systems: RIM systems centralize regulatory data and provide a single source of truth for regulatory information. They streamline regulatory processes and support data consistency. 
  • Clinical Trial Management Systems (CTMS): CTMS software assists in planning, conducting, and monitoring clinical trials. It helps with data management, regulatory compliance, and collaboration among stakeholders. 
Are your processes in line with the upcoming changes? (#RA SOP, #SOP, #Working Instructions, #Processes) 

Digitalization in pharmaceutical regulatory affairs optimizes internal processes by improving efficiency, data quality, collaboration, and decision-making, but all these improvements have a significant impact on Standard Operating Procedures (SOPs). It means that it will be necessary to: 

  • Review the internal procedures, knowing that many aspects must be considered. 
  • Determine why the SOPs need to be reviewed and updated. Clearly state the objectives of the review and the specific processes or procedures that will be evaluated. Define the scope to ensure focus. 
  • Assemble a cross-functional team that includes different stakeholders. Seek input and feedback from relevant stakeholders, including employees who perform the procedures and those affected by them. Their input is valuable in identifying areas for improvement. 
  • Compare the existing SOPs with current best practices, regulations, and industry standards. Identify gaps or areas where updates are needed. Consistency checks of language, terminology, and formatting in the SOPs should be followed to ensure they are easy to understand and followed. 
  • Prioritize the proposed changes based on their impact on safety, compliance, efficiency, and overall process effectiveness. 
  • Communicate the updates to all relevant personnel and provide training as needed to ensure they understand the changes and how to implement them. In parallel, continuously monitor the implementation of the revised SOPs. Collect feedback from employees and stakeholders to assess their effectiveness. 


In conclusion, the digital transformation has had a profound impact on pharmaceutical regulatory affairs. From streamlining processes and enhancing data analytics to promoting collaboration and compliance, digitalization has revolutionized the way regulatory affairs professionals operate. Embracing digital technologies offers immense opportunities for efficiency, speed, and innovation in drug development and regulatory submissions. However, it is essential for the industry to navigate challenges, such as cybersecurity risks and regulatory acceptance of new digital approaches, to fully realize the potential benefits of this digital revolution in pharmaceutical regulatory affairs. 

Want to know more?

Visit our  Regulatory Affairs dedicated page


Bring your product into the next generation.
Risking inspection failures is a cost no company can afford: get in touch with us and learn more together with our experts.

Connect with us